EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma
- PMID: 40348685
- DOI: 10.1016/j.jhep.2025.03.007
EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma
Abstract
Recent years have witnessed significant advances in the imaging, molecular profiling, and systemic treatment of cholangiocarcinoma (CCA). Despite this progress, the early detection, precise classification, and effective management of CCA remain challenging. Owing to recent developments and the significant differences in CCA subtypes, EASL commissioned a panel of experts to draft evidence-based recommendations on the management of extrahepatic CCA, comprising distal and perihilar CCA. Particular attention is given to the need for accurate classification systems, the integration of emerging molecular insights, and practical strategies for diagnosis and treatment that reflect real-world clinical scenarios.
Copyright © 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest M.M., L.M, L.A., J.H., no conflict of interest. JC.N. Research grants from Ipsen and Bayer. S.K. Advisory work or sponsorship for meetings from Astra Zeneca and Taiho. A.S. Honoraria from BMS, Roche, Servier, Ipsen, Lilly, AstraZeneca, MSD, Eisai, AMGEN; Travel support: Ipsen, Servier, Pierre-Fabre, MSD, Eisai; Adboard: Eisai, MSD, Roche, Incyte, BMS, Taiho. V.V., Consulting fees and Board member: Canon Medical, Guerbet, Siemens Healthinners, Bayer, Bracco; ISS: Guerbet; Industry/academic project: Siemens Healthinners, Pixyl, GE HealthCare. G.C., no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
